Drug Trial Radar · NCT02639130
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Feb 2008
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- Diabeteszentrum Bad Lauterberg im HarzAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.
Conditions
- Type 2 Diabetes
Interventions
Exendin [9-39]Drug
Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
PlaceboDrug
Placebo infusion as challenge agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of integrated insulin secretion rates (total AUC ISR) over 4 hour following the mealTime frame: 4 hour following the meal
- total AUC Glucose over 4 hour following the mealTime frame: 4 hour following the meal
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Diabeteszentrum Bad Lauterberg
Bad Lauterberg im Harz, Lower Saxony, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.